Impact of 18F-Labeled Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography Versus Conventional Staging in Patients With Locally Advanced Breast Cancer

Author(s): Ian S. Dayes, MD, MSc^1,2,3,4; Ur Metser, MD^5,6; Nicole Hodgson, MD, MSc⁷; Sameer Parpia, PhD^1,3,4; Andrea F. Eisen, MD^8,9,10; Ralph George, MD^11,12; Phillip Blanchette, MD, MSc^13,14; Tulin D. Cil, MD^6,11; Angel Arnaout, MD^15,16; Adrien Chan, MD, MPH^17,18; and Mark N. Levine, MD, MSc^1,2,3,4

Source: DOI: 10.1200/JCO.23.00249 Journal of Clinical Oncology 41, no. 23 (August 10, 2023) 3909-3916.

Dr. Maen Hussein's Thoughts

It seems that PET is better than CT scan in locally advanced disease staging, better in upstaging, and may spare the patient combined modality therapy.

PURPOSE

Patients with locally advanced breast cancer (LABC) typically undergo staging tests at presentation. If staging does not detect metastases, treatment consists of curative intent combined modality therapy (neoadjuvant chemotherapy, surgery, and regional radiation). Positron emission tomography-computed tomography (PET-CT) may detect more asymptomatic distant metastases, but the evidence is based on uncontrolled studies.

METHODS

For inclusion, patients had histological evidence of invasive ductal carcinoma of the breast and TNM stage III or IIb (T3N0, but not T2N1). Consenting patients from six regional cancer centers in Ontario were randomly assigned to 18F-labeled fluorodeoxyglucose PET-CT or conventional staging (bone scan, CT of the chest/abdomen and pelvis). The primary end point was upstaging to stage IV. A key secondary outcome was receiving curative intent combined modality therapy (ClinicalTrials.gov identifier: NCT02751710).

RESULTS

Between December 2016 and April 2022, 184 patients were randomly assigned to whole-body PET-CT and 185 patients to conventional staging. Forty-three (23%) PET-CT patients were upstaged to stage IV compared with 21 (11%) conventional staged patients (absolute difference, 12.3% [95% CI, 3.9 to 19.9]; P = .002). Consequently, treatment was changed in 35 (81.3%) of 43 upstaged PET-CT patients and 20 (95.2%) of the 21 upstaged conventional patients. Subsequently, 149 (81%) patients in the PET-CT group received combined modality treatment versus 165 (89.2%) patients in the conventional staging group (absolute difference, 8.2% [95% CI, 0.1 to 15.4]; P = .03).

CONCLUSION

In patients with LABC, PET-CT detected more distant metastases than conventional staging, and fewer PET-CT patients received combined modality therapy. Our randomized trial demonstrates the utility of the PET-CT staging strategy.

Author Affiliations

¹Department of Oncology, McMaster University, Hamilton, ON, Canada;²Juravinski Cancer Centre—Hamilton Health Sciences, Hamilton, ON, Canada;³Ontario Clinical Oncology Group, Hamilton, ON, Canada;⁴Escarpment Cancer Research Institute, Hamilton, ON, Canada;⁵Joint Department of Medical Imaging, University of Toronto, Toronto, ON, Canada;⁶University Health Network Princess Margaret Cancer Centre, Toronto, ON, Canada;⁷Department of Surgery, McMaster University, Hamilton, ON, Canada;⁸Department of Medicine, University of Toronto, Toronto, ON, Canada;⁹Sunnybrook Health Sciences Centre—Odette Cancer Centre, Toronto, ON, Canada;¹⁰Ontario Health, Toronto, ON, Canada;¹¹Department of Surgery, University of Toronto, Toronto, ON, Canada;¹²St Michael’s Hospital, Toronto, ON, Canada;¹³Department of Oncology, Western University, London, ON, Canada;¹⁴London Health Sciences Regional Cancer Program, London, ON, Canada;¹⁵Department of Surgery, Ottawa University, Ottawa, ON, Canada;¹⁶Ottawa Hospital Cancer Centre, Ottawa, ON, Canada;¹⁷Northern Ontario School of Medicine, Thunder Bay ON, Canada;¹⁸Thunder Bay Regional Health Sciences Cancer Centre, Thunder Bay, ON, Canada

Camrelizumab vs Placebo in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-Negative Breast Cancer

Another trial with neoadjuvant immunotherapy showing improved results over chemotherapy alone. (12% higher PCR 48% vs 36%).

Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable/Metastatic Hormone Receptor–Positive Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer: Primary Results From TROPION-Breast01

Dato-DXd is now approved in HR+, HER2-neg, metastatic breast cancer after prior therapy with endocrine-based therapy and chemotherapy. There was an impressive reduction in the risk of death or progression with an HR of 0.63. Watch out for ocular and pulmonary toxicity. HER2-ultra low testing will be burdensome but must be done for drug approval.

Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer

TD beat chemotherapy after failure of hormonal therapy in HER-2 low and ultra low. Wait for the indication.

Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial

MammaPrint did not predict distant recurrence, but it did predict patients who may benefit from extended hormonal therapy. We do have breast index, so now we have options. Breast index can predict the possibility of recurrence though by helping to determine the level of risk.

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

This study confirms what we saw in initial reports showing the addition of pembro increasing the rate of ypathological complete response (ypCR’s) in the neoadjuvant setting for triple-negative breast cancer (TNBC). New data shows a 5% improvement (87 vs 82%) in overall survival (OS) with the quadruplet. Higher gains but at higher cost of toxicity. The fact that adjuvant intraosseous (IO) does not seem to improve outcomes, but neoadjuvant chemo+IO does show intact tumor-immune interactions to create maximum treatment effectiveness is most likely real. Of note, this seems mostly independent of programmed death-ligand 1 (PDL1) status.